Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume 19 focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of antitumor agents. Conventional and novel anti-neoplastic agents (cytotoxic molecules, hormones/antihormones, immunotherapies) are taken into consideration, along with advances made in combination therapies. The book encompasses examples of studies on the use of antiangiogenic compounds-molecules that inhibit the growth of vessels inside a tumor-together with antineoplastic drugs in order to sensitize the resistant tumor to their cytotoxic effects, thus reducing adverse side reactions and resistance and improving the therapeutic response of cancer patients. In addition, the book discusses clinical applications in various types of cancer, such as colorectal, lung, breast, renal, genitourinary, skin and brain and circulating tumors. It is a valuable resource for cancer researchers, clinicians and members of the biomedical field who wants to be up-to-date on the most recent and promising developments in the field. Provides the most updated reviews on anti-angiogenic drugs as chemosensitizers by leaders in the field Encompasses summarized tables and schematic diagrams in each chapter to give a clear overview on recent findings in a didactic manner Brings not only relevant information of current research but also new ideas and suggestions for further investigations to help advance the field INDICE: 1. General Introduction to the book 2. Angiogenesis: definition and role, cellular and molecular mechanisms, redundancy of angiogenic modulators, receptors and converging signaling 3. Anti-angiogenic drugs (monotherapies): General characteristics; molecular mechanisms; efficacy and side effects 4. Anti-angiogenic drugs (combination therapies): molecular mechanisms; efficacy and side effects 5. Clinical applications in various cancers; state of the art of the approved protocols, ongoing clinical trials, gaps 6. Antiangiogenic drugs as chemosensitizer in colorectal cancer 7. Antiangiogenic drugs as chemosensitizer in lung cancer 8. Antiangiogenic drugs as chemosensitizer for upper GI cancer 9. Antiangiogenic drugs as chemosensitizer in breast cancer 10. Antiangiogenic drugs as chemosensitizer in renal and genitourinary cancer 11. Antiangiogenic drugs as chemosensitizer in skin cancer 12. Antiangiogenic drugs as chemosensitizer in brain tumors 13. Antiangiogenic drugs as chemosensitizer in circulating tumors 14. Antiangiogenic drugs and radiosensitization: state of the art on protocols and experimental studies 15. Resistance to combination treatments: mechanisms of resistance to antiangiogenic drugs and cross-talk with tumor cell mechanisms of resistance 16. Combination of antiangiogenic drugs with immunotherapies: efficacious synergism; side effects and limits 17. Prognostic and diagnostic biomarkers for therapy choice and to monitor antiangiogenic drug efficacy and toxicities 18. Antiangiogenic strategies: one target or multitarget inhibitors; synthetic compounds, gene therapy and natural products 19. Synthesis and application of dual inhibitors: rationale for development and state of the art of the studies 20. Metronomic therapy: mechanisms, advantages and approved protocols alone or in combination 21. Personalized medicine with tumor angiogenesis as diagnostic marker and therapeutic target 22. General Conclusions and future perspectives
- ISBN: 978-0-323-90190-1
- Editorial: Academic Press
- Encuadernacion: Cartoné
- Páginas: 294
- Fecha Publicación: 28/01/2022
- Nº Volúmenes: 1
- Idioma: Inglés